Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I took out the 38's.
I’m with you on that!
Long & Strong!
Thanks Arnie. Your calculations would also have to take into consideration the OS. For example, if CHI goes IPO with 1 Bil. shares, and since LLBO has ~ 3 Bil. OS, your pps of $3.7 will become ~$1.23.
I’ll gladly take $1.23 per LLBO share.
Plus, we need to get some thing extra for the intrinsic remaining value of LLBO, I would think.
Hi Arnie - If CHI goes IPO, they can simply replace LLBO shares with CHI shares. SO, with LLBO owning 37% of CHI, if/when CHI goes IPO, 2.7 LLBO shares will be replaced by 1 CHI IPO share. Correct? Isn't it that simple?
TIA
Gotcha!
Thanks
Fully agree with you. I expect to see this as well.
Why are we talking about Huperzine A and/or CBD? Did TSOI say something about these or are we guessing?
Thanks
+1
Hey Cody! Completely agree. I’ve been holding a lot for a long time.
We have a few significant events in the next 6 months that should allow for the pps to reflect the true value of the company and technology.
1. Issuance of the patent - April 23
2. Since there is a settlement with C2A, PTOP can now work on getting current with the SEC - Josh said that the issue with C2A was a major road-block to issuing financials and getting current.
3. Release of Beta version - I think still in Q2 (I think)
4. Full release in Q3.
5. Prod. Dev. - from business cards to resumes, etc.
I think, if done correctly, this could be huge in the next 6 months.
Any thoughts or additions?
TIA
News out!
News Release Issued: Apr 17, 2019 (3:42pm EDT)
Neovasc Announces Resolution of Last Remaining Active Litigation
NASDAQ, TSX: NVCN
VANCOUVER, April 17, 2019 /CNW/ - Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ: NVCN)(TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory angina, today announced that the Company has resolved the three claims for correction of patent inventorship made by Edwards Lifesciences CardiAQ LLC ("CardiAQ") in the United States District Court for the District of Massachusetts ("the Court").
For reasons of efficiency and economy, and without reaching the merits of the dispute, the parties agreed to a judgment ordering CardiAQ's Jeremy Brent Ratz and Arshad Quadri be added as co-inventors of U.S. Patent No. 9,241,790, U.S. Patent No. 9,248,014 and U.S. Patent No. 9,770,329, which the Court ordered. Each of these patents is directly related to and claims priority to the patent application that led to U.S. Patent No. 8,579,964, on which the Court had previously added Mr. Ratz and Dr. Quadri as co-inventors in November, 2016. In summary:
Each side agreed to bear its own fees and costs in the matter;
No money damages were at issue or awarded; and
The addition of inventors will not restrict Neovasc from practicing these patents going forward.
"We have been working diligently to clear the Company from a number of claims and the conclusion of this matter is also the conclusion of the last active claims that the Company is aware of," commented Fred Colen, Neovasc CEO. "The German Appeals Court win provided us with further strategic options to resolve these claims and we have maintained the rights to practice our entire Tiara patent portfolio of 10 granted U.S. patents and 16 pending U.S. patents in order to preserve the unique and proprietary nature of our Tiara system. We will also continue to add to this portfolio as we seek to optimize our transapical design and protect our transfemoral, transseptal version of the Tiara."
About Neovasc Inc.
Neovasc is a specialty medical device company that develops, manufactures and markets products for the rapidly growing cardiovascular marketplace. Its products include the Neovasc Reducer™ (the "Reducer"), for the treatment of refractory angina, which is not currently commercially available in the United States and has been commercially available in Europe since 2015, and the Tiara™, for the transcatheter treatment of mitral valve disease, which is currently under clinical investigation in the United States, Canada and Europe. For more information, visit: www.neovasc.com.
Certain statements in this news release contain forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and applicable Canadian securities laws that may not be based on historical fact, including without limitation statements containing the words "believe", "may", "plan", "will", "estimate", "continue", "anticipate", "intend", "expect" and similar expressions. Forward-looking statements may involve, but are not limited to, beliefs or expectations regarding the Company's ability to continue to add to its patent portfolio and the rapidly growing cardiovascular marketplace. Many factors and assumptions could cause the Company's actual results, performance or achievements to differ materially from those expressed or implied by the forward-looking statements, including, without limitation, the substantial doubt about the Company's ability to continue as a going concern; risks relating to the senior secured convertible notes (the "Notes") issued pursuant to the November 2017 private placement (the "2017 Financing"), resulting in significant dilution to the Company's shareholders; risks relating to the Company's need for significant additional future capital and the Company's ability to raise additional funding; risks relating to cashless exercise and adjustment provisions in the Notes issued pursuant to the 2017 Financing, which could make it more difficult and expensive for the Company to raise additional capital in the future and result in further dilution to investors; risks relating to the sale of a significant number of common shares of the Company; risks relating to the conversion of Notes issued pursuant to the 2017 Financing, which may encourage short sales by third parties; risks relating to the possibility that the common shares of the Company may be delisted from the Nasdaq Capital Market or the Toronto Stock Exchange, which could affect their market price and liquidity; risks relating to the Company's conclusion that it did not have effective internal control over financial reporting as at December 31, 2018; risks relating to the Company's common share price being volatile; risks relating to the influence of significant shareholders of the Company over the Company's business operations and share price; risks relating to the Company's significant indebtedness, and its effect on the Company's financial condition; risks relating to claims by third parties alleging infringement of their intellectual property rights; risks relating to lawsuits that the Company is subject to, which could divert the Company's resources and result in the payment of significant damages and other remedies; the Company's ability to establish, maintain and defend intellectual property rights in the Company's products; risks relating to results from clinical trials of the Company's products, which may be unfavorable or perceived as unfavorable; the Company's history of losses and significant accumulated deficit; risks associated with product liability claims, insurance and recalls; risks relating to use of the Company's products in unapproved circumstances, which could expose the Company to liabilities; risks relating to competition in the medical device industry, including the risk that one or more of the Company's competitors may develop more effective or more affordable products; risks relating to the Company's ability to achieve or maintain expected levels of market acceptance for the Company's products, as well as the Company's ability to successfully build its in-house sales capabilities or secure third-party marketing or distribution partners; the Company's ability to convince public payors and hospitals to include the Company's products on their approved products lists; risks relating to new legislation, new regulatory requirements and the efforts of governmental and third-party payors to contain or reduce the costs of healthcare; risks relating to increased regulation, enforcement and inspections of participants in the medical device industry, including frequent government investigations into marketing and other business practices; risks associated with the extensive regulation of the Company's products and trials by governmental authorities, as well as the cost and time delays associated therewith; risks associated with post-market regulation of the Company's products; health and safety risks associated with the Company's products and industry; risks associated with the Company's manufacturing operations, including the regulation of the Company's manufacturing processes by governmental authorities and the availability of two critical components of the Reducer; risk of animal disease associated with the use of the Company's products; risks relating to the manufacturing capacity of third-party manufacturers for the Company's products, including risks of supply interruptions impacting the Company's ability to manufacture its own products; risks relating to the Company's dependence on limited products for substantially all of the Company's current revenues; risks relating to the Company's exposure to adverse movements in foreign currency exchange rates; risks relating to the possibility that the Company could lose its foreign private issuer status under U.S. federal securities laws; risks relating to breaches of anti-bribery laws by the Company's employees or agents; risks associated with future changes in financial accounting standards and new accounting pronouncements; risks relating to the Company's dependence upon key personnel to achieve its business objectives; the Company's ability to maintain strong relationships with physicians; risks relating to the sufficiency of the Company's management systems and resources in periods of significant growth; risks associated with consolidation in the health care industry, including the downward pressure on product pricing and the growing need to be selected by larger customers in order to make sales to their members or participants; risks relating to the Company's ability to successfully identify and complete corporate transactions on favorable terms or achieve anticipated synergies relating to any acquisitions or alliances; risks relating to the Company's ability to successfully enter into fundamental transactions as defined in the Notes issued pursuant to the 2017 Financings; anti-takeover provisions in the Company's constating documents which could discourage a third party from making a takeover bid beneficial to the Company's shareholders; and risks relating to conflicts of interests among the Company's officers and directors as a result of their involvement with other issuers. These risk factors and others relating to the Company are discussed in greater detail in the "Risk Factors" section of the Company's Annual Report on Form 20-F and in the Management's Discussion and Analysis for the year ended December 31, 2018 (copies of which may be obtained at www.sedar.com or www.sec.gov). The Company has no intention and undertakes no obligation to update or revise any forward-looking statements beyond required periodic filings with securities regulators, whether as a result of new information, future events or otherwise, except as required by law.
SOURCE Neovasc Inc.
For further information: Chris Clark, Chief Financial Officer, Neovasc Inc., 604 248-4138, cclark@neovasc.com; Jeremy Feffer, LifeSci Advisors, LLC, 212-915-2568, jeremy@lifesciadvisors.com
To unsubscribe or change your settings click here:
https://neovasc.mediaroom.com/index.php?s=subscribe&code=4pj8YP7NrTG8DFnkG93rseiGtRsjvFH7
Thanks pro. Any thoughts or interpretations of the 10k from the longs?
Hello fellow Long’s,
I’d like to add that those who are buying the offering at 0.005 want a HUGE RETURN - 5-10 times their investment? So I am looking at pennies in the near future.
Now, the question I have is, what is the incentive to buy at 0.005, when they can buy at 0.0006 - 0.0008 on the open market?
If someone could help me understand this, I would be great-full.
Thanks
L&S
Awesome! I don’t have PM capabilities, but if u do, drop Monte or askshleg a note to connect with other longs through a diff ave.
L&S
Hey Monte, unfortunately, I don’t have PM abilities - but, yes! would love to.
Please share what you know.
TIA
Hey Jon,
I was in HMNY as well and lost a bunch. No worries. I chalk it up to a learning experience.
RS is possible. But, I invested in the validity of the technology. I strongly believe (there is an element of hope) that this will get to the numbers I was coming up with.
So, patience and fortitude are the drivers for me.
See you on the long!
Arnie, I am in agreement with you. No doubt. But, I post to discuss, learn and understand, and grow.
That said, my point was very simple: our current OS needs to be taken into consideration irrespective of the scenario or path forward. That’s all.
I want to be realistic in my on expectations. With 3+B OS, we cannot expect the ‘final’ pps would be $1. It simply cannot.
I do agree with you and MEAD that we will be big, any where from $0.04 to $0.08 by end of next year, if acquisitions, partnerships, etc. happen.
IMO.
Hey UVA, NSX, font, SFT, Chaka, and other longs,
I just thought I’d share my thought process.
Revenues for 2018 = app 125k
OS = app 1B
To have a pps of $0.01, we are at app. 80x
Now, imagine Q1 revs to be 100k (we know it is going to be more)
Now, assume we don’t add any additional docs and we stabilize at 100k per Q = 400k for 2019. ( we know we’ve adding docs and this number will at least be double = 800k). This also assumes that we make no progress on any other front, including FemCelz, which is already being marketed. Now, all things being equal (no Chang in OS), our pps will be app. $0.04 for 2019.
However, we are adding docs every Q. So, if we add 3 docs per Q - for a full Q, we grow by app. $100k from previous Q - assuming we had Revs of $100k in Q4 with 3 docs fully performing for the entire Q. So, our Revs for 2019, will become, after we increase by $100k per Q by adding 3 docs per Q, app. $1.3M, which at the same 80x, gives us a pps of $0.104. This will be realized after the Q1 2020.
Now, let’s talk about fully diluted pps. If the logic from above holds and we get to 1.3B OS, our pps at the end of this year will be app. $0.08.
As OS increases, 80x will be reduced by app. same %, so worst case, we will see a pps of app. $0.06. This is assuming ‘no changes in every thing else’. This is the ultimate worst case!
Please tell me what u think. If you need details of the math, let me know.
Now, I see that there are many other patents and avenues for generating additional revs. So, reality for me is that the pps will be higher than my estimates. How much higher? Don’t know.
Hi MEAD and ARNIE.
Agree with both of you. The one thing that I want to remember and be realistic about is that LLBO has 3.35B OS. So, in the scenario where CHI absorbs/Buys LLBO and goes IPO, I think we should not assume that all 3.35B LLBO will be replaced 1 to 1 by CHI. I am prepared for s 1 to 10 or 1 to 100 (which will give us a pps is $1 or $0.10 if CHI shares are $10). Or the replacement will be a formula related to or derived by using 37% ownership.
Just my thoughts. Patience will tell us soon enough.
Long and Strong!
I am with you in that this is a life time opportunity. I had posted earlier that along with all the dd by ‘cents’ and the Share structure - with 80% of the OS as restricted and a float of only 105mm/ this is golden.
Just buy and hold. That’s my plan.
Thanks MEAD. Just wanted to confirm.
L&S
Agreed and understood. My question was more related to people posting the reasons why they think that TSOI is a buy out candidate and not an organic growth co ( mgmt cannot cash in their restricted shares like common shares unless they sell the company).
Let’s stay patient and go for the long term.
Thanks.
I saw those pics. And I think they are building a clean room to increase R&D and Mfg capabilities.
Is it really true that the only way the insiders can sell their restricted shares via a buy out?
Thx NSX. I would be retiring at those prices too.
I wonder if CMTH MGMT would ever consider selling the company.
C u all in Vegas
I always enjoy your dd cents.
In addition to your dd, I was checking, again, the share structure.
1.1 billion OS, ~900 million restricted, 200 million unrestricted and 105 million float.
How can this Not be an opportunity of a lifetime?
Wow! Locked and loaded! L&S
Hey NSX - your mouth to God’s ears - especially the last sentence.
What do you need the pps to be in 3 years for you to retire? Just trying to gauge my own position as I am Super Ling as well.
TIA for all the work you and other Longs are doing.
Don’t forget the acquisition of health clinics. These can add to the numbers very quickly. Any idea of how many clinics there were?
is there any indication/implication that Bayer may be interested in LLBO?
Good Morning MEAD. I agree with everything you said. My point is that to go directly from FDA announcement to an immediate start in pps increase, without a lot of intermediate steps - some of which you mention - is challenging. That’s all.
I do agree that the tides are changing, but it will take a little time and patience for the pps to go up.
Waiting for the K’s and Q’s. Thanks and Good Luck to all.
L&S
Hi Arnie, while I respect your posts and position, I am not sure why the announcement would trigger an increase in LLBO pps, especially starting Monday. I can see the LLBO pps increasing if the mgmt comes out with an announcement connecting LLBO to/with the FDA announcement. And this has to happen quickly to impact the pps positively.
I still believe in LLBO technology and that, as announced by the LLBO mgmt previously, things can happen towards the end of this year.
JIMHO. Long & Strong
This is GREAT NEWS! Nice find fish. Thanks.
As some/all longs have been saying, we need to have patience and wait for 1 year to see solid results from LLBO.
I am confident that the LLBO mgmt is aware of this and will capitalize on this news.
L&S
Hi all,
All I expect from the MGMT is that they show me improving revenues Q over Q. That’s all.
The rest, that everyone is worried/talking/screaming etc. over, simply leads to the Q over Q, year over Year. Simple.
Till Vegas - unless I have or find something else to add.
Long and Strong!
Hi Kent. I’ve never seen any of the ‘rumors, murmurs & buzz’ predictions come true.
May be this time?????
I just know that TSOI is worth waiting for.
L&S
Same here Cody et. al.
I'm in it for the Long term as well. I believe that the product has great potential and after the dust settles, we will be ok. It ill take time and patience.
L&S
Monte - Don't go quiet now. Please tell us what you think.
Cody and Eazy, I had the same questions. There was no public info regarding the topic in his email. And, the email he claims to have received would have been drafted as a standard email to all impacted/affected - therefore, triple, quadruple checked.
I think the statements in the post regarding the email is not true.
JIMHO
Good to know Chaka. CELZ and TSOI both MGMT are super quiet. Hmmmmm!
You know what they say - Better Lucky than Good!
Ha Ha! Any thoughts on when TSOI is having their 2018 Annual update? or 2018Q4 update?
Too quiet!